Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension-A Randomized Trial"
- PMID: 31688273
- DOI: 10.1097/SLA.0000000000003680
Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension-A Randomized Trial"
Comment in
-
Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial".Ann Surg. 2020 May;271(5):e122. doi: 10.1097/SLA.0000000000003675. Ann Surg. 2020. PMID: 31714314 No abstract available.
Comment on
-
Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial.Ann Surg. 2019 Jun;269(6):1025-1033. doi: 10.1097/SLA.0000000000003062. Ann Surg. 2019. PMID: 31082898 Clinical Trial.
References
-
- Troisi RI, Vanlander A, Giglio MC, et al. Somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension: a randomized trial. Ann Surg 2019; 269:1025–1033.
-
- Kim JH. Effects of portal hyperperfusion on partial liver grafts in the presence of hyperdynamic splanchnic circulation: hepatic regeneration versus portal hyperperfusion injury. Anaesth Pain Med 2016; 11:117–129.
-
- Reddy MS, Rela M. Portosystemic collaterals in living donor liver transplantation: what is all the fuss about? Liver Transpl 2017; 23:537–544.
-
- Byun SH, Yang HS, Kim JH. Liver graft hyperperfusion in the early postoperative period promotes hepatic regeneration 2 weeks after living donor liver transplantation: a prospective observational cohort study. Medicine (Baltimore) 2016; 95:e5404.
-
- Feng AC, Fan HL, Chen TW, et al. Hepatic hemodynamic changes during liver transplantation: a review. World J Gastroenterol 2014; 20:11131–11141.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources